1 / 5

Psoriasis Therapeutics Market worth 1.2 Billion by 2021

The Psoriasis treatment landscape is a particularly complex one. More than 80% of patients fall into the mild-or-moderate category, for which the first line of treatment is topical drugs, phototherapy, or a combination.

MIR114
Download Presentation

Psoriasis Therapeutics Market worth 1.2 Billion by 2021

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Psoriasis Therapeutics in Asia- Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth Published on – 01 May, 2015 | Number of pages : 91 Single User Price: $4995 “In 2014, the value of the psoriasis therapeutics market in APAC amounted to an estimated $690m, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.4% between 2014 and 2021 to reach $1.2 billion.”

  2. Summary of the Report:MarketIntelReports Research, the leading business intelligence provider, has released its latest research, "Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth", which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. In 2014, the value of the Psoriasis Therapeutics Market in APAC amounted to an estimated $690m, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.4% between 2014 and 2021 to reach $1.2 billion. The psoriasis treatment landscape is a particularly complex one. More than 80% of patients fall into the mild-or-moderate category, for which the first line of treatment is topical drugs, phototherapy, or a combination. In the case of severe patients, non-steroidal drugs such as methotrexate, cyclosporine, and acitretin are practiced as first-line treatment; however, they come with toxicity concerns and so cannot be prescribed for long durations. Click Here To Check Complete Report

  3. Scope of the Report: • The report analyzes treatment use patterns, market characterization, the pipeline, and key licensing and co-development deals for psoriasis in the APAC markets of China, India, Japan, and Australia.The report includes - • A brief introduction to psoriasis, including pathophysiology, etiology, diagnosis, and treatment algorithms • In-depth analysis of currently marketed drugs, including analysis of safety, efficacy, treatment patterns, and strengths/weaknesses, along with a heat map comparing them in terms of safety and efficacy • A comprehensive review of the pipeline for psoriasis, including individual analysis of a number of late-stage pipeline drugs likely to enter the market during the forecast period; the pipeline is further analyzed on the basis of phase distribution, molecule type, program type, mechanism of action, and molecular target • Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration, and program failure rate for each molecule type Download Sample Brochure

  4. Reasons to buy: • The report will enhance your decision-making capability by allowing you to - • Understand the psoriasis pipeline and the factors that indicate that it is becoming more innovative • Analyze detailed profiles for promising pipeline products and gain insights into how they are likely to compete in the market and who their main competitors will be • Follow the trends in psoriasis clinical trial size and duration in relation to industry averages • Assess the potential risk of future developmental programs for psoriasis therapeutics by mechanism of action using recorded clinical trial failure rates • Analyze the potential growth patterns expected for the psoriasis market over the forecast period • Identify the countries that are expected to contribute the most to this growth and devise a more effectively tailored country strategy through an understanding of key drivers and barriers • Accelerate and strengthen your market position by identifying key companies for strategic partnerships Make an Inquiry Before Buying

  5. Psoriasis Therapeutics in Asia- Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth A detailed qualitative analysis of the factors responsible for driving and restraining growth of the Psoriasis Therapeutics Market are provided in the report. Contact: 1-302-684-6088 sales@marketintelreports.com www.marketintelreports.com Click here to order a copy of Psoriasis Therapeutics Market Report

More Related